The Role of Antidiabetic Drugs in Bone Health: Assessing the Risk of Osteoporosis Subtypes and Fractures Using Mendelian Randomization
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: Osteoporosis leads to decreased bone density and an increased risk of fractures, with diabetic patients being particularly vulnerable. This study aims to evaluate the effects of five common antidiabetic drugs-Metformin, GLP-1 receptor agonists, SGLT2 inhibitors, Insulin, and Gliclazide-on the risk of osteoporosis subtypes and fractures, using Mendelian Randomization (MR) to ensure result accuracy. Methods: Data from multiple Genome-Wide Association Studies (GWAS) databases were employed to assess the relationships between the use of these antidiabetic drugs and osteoporosis risk. The analysis utilized Mendelian Randomization techniques to minimize confounding and reverse causation, ensuring robust results. Results: ), indicating a potential bone-protective effect by reducing bone resorption and enhancing osteoblast activity through the activation of the AMPK pathway. GLP-1 receptor agonists are significantly positively associated with osteoporosis with pathological fractures (OR [95% CI]: 1.1247 [1.0043-1.2594], p = 0.0420), suggesting a potential increase in fracture risk. SGLT2 inhibitors show a weak negative association with osteoporosis (OR [95% CI]: 0.8987 [0.8092-0.9980], p = 0.0429), though the effect is minor and unstable. Gliclazide significantly increases the risk of pathological fractures (OR [95% CI]: 1.03E+08 [1.28E+02-8.32E+12], p = 0.0395), indicating a need for caution in its use among patients at high fracture risk. Discussion: The results highlight the potential bone-protective role of Metformin, which may be suitable for patients at high fracture risk. On the other hand, the use of GLP-1 receptor agonists and Gliclazide should be carefully considered, especially in individuals with osteoporosis or at high risk of fractures. These findings emphasize the importance of personalized medication management in diabetic patients to optimize bone health.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The Role of Antidiabetic Drugs in Bone Health: Assessing the Risk of Osteoporosis Subtypes and Fractures Using Mendelian Randomization
- Date Crossref
- 01/04/2025
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Second Affiliated Hospital of Xi'an Jiaotong University Department of Biodiagnostics and Biotherapy pays non établi dans la noticeÉtablissement de santé
-
Jiangxi Science and Technology Normal University pays non établi dans la noticeUniversité ou école supérieure
-
Nanchang University Department of Orthopaedics pays non établi dans la noticeUniversité ou école supérieure
-
Jiangxi Provincial People's Hospital pays non établi dans la noticeÉtablissement de santé
-
Second Affiliated Hospital of Nanchang University pays non établi dans la noticeÉtablissement de santé
-
First Affiliated Hospital of Nanchang University pays non établi dans la noticeÉtablissement de santé
-
College of Life Science pays non établi dans la noticeUniversité ou école supérieure
Department of Biodiagnostics and Biotherapy — Second Affiliated Hospital of Xi'an Jiaotong University, Jiangxi Science and Technology Normal University et Department of Orthopaedics — Nanchang University, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.